The Standard of Care for EGFR Exon 20 Insertion+ Lung Cancer
In Partnership With
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the current standard of care for EGFR exon 20 insertion-mutated lung cancer.
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the current standard of care for EGFR exon 20 insertion-mutated lung cancer.
According to Spira, the current standard of care for this disease is chemotherapy alone. However, 1 new drug is in the pipeline for approval, the tyrosine kinase inhibitor (TKI) known as mobocertinib. A monoclonal antibody known as amivantamab (Rybrevant) was recently granted FDA approval for the treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 insertion mutations. The approval was the result of positive data from the phase 1 CHRYSALIS clinical trial (NCT02609776).
Both agents have reasonable response rates. Mobocertinib has a response rate in the mid to high 20% range as a second-line therapy. Amivantamab offers a slightly higher response rate, says Spira. Both drugs also appear to be well tolerated
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
